Back to Search Start Over

Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoea

Authors :
Ong, Jason J.
Aguirre, Ivette
Unemo, Magnus
Kong, Fabian Y. S.
Fairley, Christopher K.
Hocking, Jane S.
Chow, Eric P. F.
Tieosapjaroen, Warittha
Ly, Jenny
Chen, Marcus Y.
Ong, Jason J.
Aguirre, Ivette
Unemo, Magnus
Kong, Fabian Y. S.
Fairley, Christopher K.
Hocking, Jane S.
Chow, Eric P. F.
Tieosapjaroen, Warittha
Ly, Jenny
Chen, Marcus Y.
Publication Year :
2022

Abstract

OBJECTIVES: Azithromycin is commonly used to treat Neisseria gonorrhoeae. We compared its gastrointestinal side effects using 1 g single, 2 g single or 2 g split (i.e. 1 g plus 1 g 6-12 h later) dosing, representing our clinic's changing guidelines over the study period. METHODS: We recruited consecutive sexual health clinic patients who received azithromycin (and 500 mg ceftriaxone) for uncomplicated gonorrhoea. Each patient received a text message 48 h after their attendance to complete a questionnaire. RESULTS: Patients received 1 g single (n = 271), 2 g single (218) or 2 g split (105) doses. Vomiting was less common for 1 g versus 2 g single dose [1.1% versus 3.7%; risk difference (RD): -2.6%; 95% CI: -0.2 to -5.4] and 2 g split versus 2 g single dose (0.9% versus 3.7%; RD: -2.8%; 95% CI: -0.3 to -5.8). Nausea was less common for 1 g versus 2 g single dose (13.7% versus 43.1%; RD: -29.5%; 95% CI: -21.7 to -37.2) and 2 g split versus 2 g single dose (16.4% versus 43.1%; RD: -26.8; 95% CI: -17.2 to -36.3). Diarrhoea was less common for 1 g versus 2 g single dose (25.5% versus 50.9%; RD: -25.5%; 95% CI: -17.0 to -33.9) and 2 g split versus 2 g single dose (30.9% versus 50.9%; RD: -20.0; 95% CI: -9.1 to -30.9). Almost all were willing to retake the same dosing for gonorrhoea in the future: 97% for 1 g single; 94% for 2 g single; and 97% for 2 g split dose. CONCLUSIONS: Azithromycin 2 g split dose for gonorrhoea resulted in significantly less vomiting, nausea and diarrhoea than a 2 g single dose.<br />Funding agency:National Health and Medical Research Council (NHMRC) of Australia GNT1193955 GNT1172873 GNT1172900 GNT1136117

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1337536887
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1093.jac.dkac118